Noramco, a prominent global manufacturer of active pharmaceutical ingredients (APIs) specializing in controlled substances, has revealed the Noramco Group, a comprehensive North American-based supply chain solution. 

This initiative integrates subsidiaries Purisys, Noramco, and recently acquired drug product CDMO, Halo Pharma, to enhance the region's clinical and commercial API and drug product supply chain.

The announcement comes in response to mounting drug shortages and quality concerns in the United States, exacerbated by unreliable foreign supply, limited domestic manufacturing capacity, and logistical challenges. The COVID-19 pandemic further highlighted the vulnerabilities of the globalized supply network, prompting Noramco to champion a shift towards increased domestic production and enhanced supply chain performance in North America.

Lee Karras, CEO of the Noramco Group, emphasized the critical need for this strategic alignment, citing the vulnerabilities exposed by the pandemic and the importance of proactive solutions. He stated, "The formation of the Noramco Group is our proactive solution to some of these challenges. We are uniquely positioned to provide our customers with a complete, North American-based supply chain solution."

Noramco, headquartered in Wilmington, Delaware, supplies commercial APIs globally for medical treatments such as pain management and drug abuse treatment. Purisys, based in Athens, Georgia, specializes in clinical API development and manufacturing, particularly focusing on controlled substances and pharmaceutical reference standards. Halo Pharma, operating in Whippany, New Jersey, and Montreal, Quebec, offers contract development and manufacturing services for diverse dosage forms.

The integration of these entities aims to streamline industry processes, reduce logistics costs, and enhance regulatory compliance. Notable benefits include improved protection of intellectual property and increased opportunities for securing government grants and contracts, particularly for pharmaceutical and biotech companies working with New Chemical Entities (NCEs).